{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2006"],"condition":["Colorectal Cancer","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2033619"],"location":["Israel"],"study_start_month":["10"],"keyword":["Leucovorin","Colorectal cancer, DAVANAT, colon cancer, 5-FU","Fluorouracil","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Withdrawn"],"additional_accession":[]},"is_claimable":false,"name":"A New Agent GM-CT-01 in Combination With 5-FU, Avastin and Leucovorin in Subjects With Colorectal Cancer","description":"The purpose of this clinical trial is to determine whether the combination of 5-fluorouracil (5-FU) plus a DAVANAT (carbohydrate polymer) along with Avastin and Leucovorin (LV) is beneficial in treating colorectal cancer in patients unable to tolerate intensive chemotherapy.","dates":{"creation":"2006-10-15"},"accession":"2033619","cross_references":{"ClinicalTrials___gov":["NCT00388700"]}}